scholarly journals SURVIVORS OF SUDDEN CARDIAC ARREST IN THE PRESENCE OF MYOCARDIAL INFARCTION: SECONDARY PROTECTION WITH THE WEARABLE CARDIOVERTER DEFIBRILLATOR

2014 ◽  
Vol 63 (12) ◽  
pp. A275
Author(s):  
Nicole R. Bianco ◽  
Steven Szymkiewicz
Keyword(s):  
Myocardial Infarction ◽  
Cardiac Arrest ◽  
Sudden Cardiac Arrest ◽  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator

scholarly journals Health Technology Assessment on the use of the Wearable Cardioverter Defibrillator in Patients with Myocardial Infarction and with ICD Explant

2021 ◽  
Vol 22 (1S) ◽  
Author(s):  
Paolo Angelo Cortesi ◽  
Giovanni Luca Botto ◽  
Lucia D'Angiolella ◽  
Luciana Scalone ◽  
Roberto De Ponti ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Cardiac Arrest ◽  
Health Technology Assessment ◽  
Implantable Cardioverter Defibrillator ◽  
Technology Assessment ◽  
Sudden Cardiac Arrest ◽  
Health Technology ◽  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator ◽  
Patients At Risk

The objective of the present work is to conduct a Health Technology Assessment (HTA) on the use of the Wearable Cardioverter Defibrillator (WCD) in patients at risk of Sudden Cardiac Arrest (SCA) following Myocardial Infarction (MI) or with an explanted Implantable Cardioverter Defibrillator (ICD).

Abstract 55: Ventricular Fibrillation remains the Primary Presenting Rhythm: Results from the Wearable Cardioverter Defibrillator Human Study

Circulation ◽  
2007 ◽  
Vol 116 (suppl_16) ◽  
Author(s):  
Hao Wang ◽  
Wanchun Tang ◽  
Min-Shan Tsai ◽  
Yongqin Li ◽  
Max H Weil
Keyword(s):  
Cardiac Arrest ◽  
Ventricular Fibrillation ◽  
Clinical Studies ◽  
Human Study ◽  
Sudden Cardiac Arrest ◽  
Pulseless Electrical Activity ◽  
Progressive Decrease ◽  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator ◽  
Initial Rhythm

Background. Clinical studies during the last 2 decades have demonstrated a progressive decrease in the incidence of ventricular fibrillation (VF) as the presenting rhythm in settings of out-of-hospital sudden cardiac arrest (SCA). In the present study, we investigated the initial rhythm of SCA from data recorded in a wearable cardioverter defibrillator (WCD) which collected these events in real time. Hypothesis. In settings of out-of-hospital SCA, VF remains the leading cause. Methods and Results. The incidence and the type of arrhythmias were determined by reviewing stored electrocardiograms in the WCDs. Seventy-four consecutive WCD recipients and 108 events were analyzed. Patients with a previously implanted ICD that required change due to infection were the most prevalent recipients of WCDs. Fifty-one percent were VF/VT patients and 43.8% were pulseless electrical activity (PEA) patients. VF/VT was the initial rhythm of SCA in 79.7% of patients and 86.1% of events while the PEA occurred in 20.3% of patients and 13.9% of events. 84.5% of patients survived VF/VT and 18.8% of patients survived PEA. There was no difference in the characteristics of patients with different initial rhythms. Conclusions. In out-of-hospital settings, VF remains the predominant initial rhythm when recorded immediately following SCA. .

scholarly journals Sudden Cardiac Arrest in Hemodialysis Patients with Wearable Cardioverter Defibrillator

2013 ◽  
Vol 19 (3) ◽  
pp. 247-257 ◽  
Author(s):  
Chingping Wan ◽  
Charles A. Herzog ◽  
Wojciech Zareba ◽  
Steven J. Szymkiewicz
Keyword(s):  
Cardiac Arrest ◽  
Sudden Cardiac Arrest ◽  
Hemodialysis Patients ◽  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator

PP002 Sudden Cardiac Arrest: Wearable Cardioverter-Defibrillator Therapy

2017 ◽  
Vol 33 (S1) ◽  
pp. 68-68
Author(s):  
Sabine Ettinger ◽  
Michal Stanak ◽  
Mirjana Huic ◽  
Romana Tandara Hacek ◽  
Darija Ercevic ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Focus Group ◽  
Adverse Events ◽  
Cardiac Disease ◽  
Sudden Cardiac Arrest ◽  
The Body ◽  
Cochrane Library ◽  
Cardioverter Defibrillator ◽  
Wearable Cardioverter Defibrillator ◽  
Wide Range

INTRODUCTION:Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. Mostly, ventricular tachycardia (VT) and ventricular fibrillation (VF) are the underlying aetiology of SCA, which is claimed to be successfully treated by a novel therapy, a wearable cardioverter defibrillator (WCD, LifeVest®).The assessment, performed within the European Network for HTA (EUnetHTA), aimed to provide valid data on clinical effectiveness and safety of the WCD. Furthermore, the project intended to elicit patients views on aspects regarding their cardiac disease and the WCD therapy as well as to identify neglected outcomes.METHODS:A synthesis of evidence on the basis of a systematic literature search in Medline via Ovid, Embase, the Cochrane Library, and the Centre for Reviews and Dissemination (CRD) databases was performed. The search was complemented by citation tracking and handsearch.A face-to-face semi-structured focus group interview was performed with five cardiac disease patients in the scoping phase.RESULTS:Since no prospective controlled trials were found, no assessment of effectiveness could be performed. With regard to safety, five prospective studies were included, but the quality of the body of evidence was very low. Adverse events (AEs) reported were skin rash/itching (6 percent), false alarms (14 percent), palpitations/lightheadedness/fainting (9 percent) and discontinuation due to comfort/lifestyle issues (16-22 percent). Serious adverse events (SAEs) were inappropriate shocks (0-2 percent) and unsuccessful shocks (0-.7 percent). Frequency of SAEs leading to death was 0-.3 percent.Patients of the focus group reported that experiencing a sense of security was crucial to them. The WCD therapy was not considered an option for weeks or months, due to expected restrictions in living a ‘normal’ and secure life.CONCLUSIONS:No statement can be made about the device effectiveness – further research is needed. More data and more adequate reporting of AEs and SAEs are needed in order to establish the device safety. In particular, more data is needed for risk stratification of high risk patients in order to further narrow down the wide range of indications for the WCD use.

Abstract 19529: Risk of Sudden Cardiac Arrest According to the Month of STEMI Occurrence: The e-MUST Study

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Nicole Karam ◽  
Muriel Tafflet ◽  
Sophie Bataille ◽  
Eloi Marijon ◽  
Jean Philippe empana ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Cardiac Arrest ◽  
Emergency Medical Services ◽  
Cause Of Death ◽  
Sudden Cardiac Arrest ◽  
Temporal Changes ◽  
Pathophysiological Mechanisms ◽  
Hospital Study ◽  
Suspected Acute Myocardial Infarction

STEMI mortality decreased drastically during the last decades, and out-of-hospital sudden cardiac arrest (SCA) has become its main cause of death. The risk of SCA according to the month of STEMI occurrence has not been assessed. Hypothesis: The risk of SCA varies according to the month of STEMI occurrence. Methods: Data were taken from a prospective pre-hospital study (e-MUST study) on STEMI patients managed by emergency medical services in Paris and its suburbs between January 2006 and December 2010. In this area, emergency calls are routed to the closest dispatch center and regulated by physicians who send an ambulance with a physician on board in case of suspected acute myocardial infarction. Pre-hospital EKGs are obtained for all patients and those presenting STEMI are included in the study. We assessed and compared the rate of SCA according to the month of STEMI occurrence. Results: Among the 8112 STEMI patients enrolled (mean age (SD) 61.6years (14.3), 78% males), 452 patients (5.6%) developed out-of-hospital SCA. We observed significant temporal changes in the rate of SCA per STEMI over the year. The peak rate of SCA per STEMI occurred in June (8.7%), while the lowest rate was in December (3.45%) (Figure). Conclusions: The risk of SCA varies significantly according to the month of STEMI occurrence, with STEMI occurring in June being at the highest risk for SCA while those occurring in December have the lowest risk. A better understanding of the pathophysiological mechanisms of this difference is needed to eventually reduce the risk of out-of-hospital SCA after STEMI diagnosis.

Sign in / Sign up

Export Citation Format

Share Document